At the end of 2016, Aerie Pharmaceuticals had 95 employees and a lead drug candidate, Rhopressa, it hoped to launch next year. Now, Aerie has that hoped-for FDA approval—and it's preparing to hire 100 ...

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies ...

Aerie Pharmaceuticals, Inc. AERI announced that the FDA has approved its lead candidate, Rhopressa (netarsudil ophthalmic solution) 0.02% for the lowering of elevated intraocular pressure (IOP) in ...

The FDA has completed its initial 60-day review of the New Drug Application (NDA) for Rhopressa (netarsudil; Aerie) 0.02% and determined that it's sufficiently complete to permit a substantive review.

The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted favorably on questions of efficacy regarding Aerie Pharmaceuticals’ glaucoma drug Rhopressa. Rhopressa (netarsudil ophthalmic ...

(Reuters) - Aerie Pharmaceuticals Inc's experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits ...

The NDA (new drug application) for Rhopressa TM (netarsudil ophthalmic solution) 0.02% was submitted to the U.S. Food and Drug Administration (FDA) in February 2017, and, in May 2017, the FDA set the ...

Please provide your email address to receive an email when new articles are posted on . Aerie Pharmaceuticals recently announced the FDA approval of Rhopressa, a first-in-class therapy for the ...

Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story. The pharmaceutical company, which ...

Aerie Pharmaceuticals Inc. announced Monday afternoon that the Food and Drug Administration has approved a medication developed to relieve pressure in patients suffering from glaucoma or ocular ...